Company: EDSA
Filing Date: 2025-03-04
Form Type: S-3
Source: 0001171843-25-001239
Chunk: 10

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-04
Form: S-3
Chunk 10
---
 factors are
beyond our control. Future events may vary substantially from what we currently foresee. You should not place undue reliance on such forward-looking
statements. We are under no obligation to update or alter such forward-looking statements whether as a result of new information, future
results, events, developments or otherwise, unless required to do so by a governmental authority or applicable law. We advise you, however,
to review any further disclosures we make on related subjects in our most recent Annual Report on Form 10-K, as well as any amendments
thereto reflected in subsequent filings with the SEC.

| 6 |

<div align='center'>USE OF PROCEEDS</div>

All of our common shares offered by this prospectus
are being registered for the accounts of the Selling Shareholders, and we will not receive any proceeds from the sale of the common shares.

| 7 |

<div align='center'>SELLING SHAREHOLDERS</div>

This prospectus covers the resale or other disposition
by the Selling Shareholders identified in the table below of up to an aggregate of 7,812,496 common shares, which are comprised of (i)
3,468,746 Shares and (ii) 4,343,750 Conversion Shares.

The Selling Shareholders acquired their securities
in the transaction described above under the heading “Prospectus Summary – Recent Developments – Private Placement.”

The table below sets forth, as of February 28, 2025,
the following information regarding the Selling Shareholders:

| · | the name of the Selling Shareholder; |

| · | the number of common shares owned by the Selling Shareholder prior to this offering, without regard to any beneficial ownership limitations; |

| · | the number of common shares to be offered by the Selling Shareholder in this offering; |

| · | the number of common shares to be owned by the Selling Shareholder assuming the sale of all of the common shares covered by this prospectus; and |

Except as described above, the number of common shares
beneficially owned by the Selling Shareholder has been determined in accordance with Rule 13d-3 under the Exchange Act and includes, for
such purpose, common shares that the Selling Shareholder has the right to acquire within 60 days of February 28, 2025.

All information with respect to the
common share ownership of the Selling Shareholders has been furnished by or on behalf of the Selling Shareholders. We believe, based on
information supplied by the Selling Shareholders